Skip to content

The Association Between Areca-nut Chewing Habit and Metabolic Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02175524
Enrollment
200
Registered
2014-06-26
Start date
2014-04-30
Completion date
Unknown
Last updated
2014-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome., Oral and Esophageal Cancer

Keywords

nut chewing

Brief summary

The purpose of this study is going to determine the odds ratio of metabolic syndrome (MS), the habit of areca nut chewing, antioxidant, and inflammatory status in oral and esophageal patients. The current study was designed as a case-control study. Patients proved to be oral and esophageal cancer and had the habit of areca nut chewing are defined as case group. Patients proved to be oral and esophageal cancer and did not have the habit of areca nut chewing are defined as control group. The participants' age, blood pressures, and smoking habits will be recorded. Body weight, height, waist, and hip circumferences will be measured. Fasting venous blood samples will be obtained to determine hematological parameters \[i.e., serum creatinine, total cholesterol, triacylglycerol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, malondialdehyde, superoxide dismutase, glutathione peroxidase, catalase, and inflammatory markers (C-reactive protein, tumor necrosis factor-alpha, and interleukin-6)\]. Logistic regression analyses are going to perform to examine the relationship between areca nut chewing and MS in this population. If we can make sure the relationship between areca nut chewing and MS, the clinicians and nutritionists can teach people to quit areca nut chewing in order to avoid the possibility of developing metabolic syndrome and cardiovascular disease.

Interventions

None listed

Sponsors

Taichung Veterans General Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients proved to be oral and esophageal cancer will be recruited.

Exclusion criteria

* Subjects with diabetes mellitus, liver, renal diseases, or undergoing statin therapy. * Taking antioxidant vitamins supplements.

Design outcomes

Primary

MeasureTime frameDescription
Metabolic syndromeUp to 1 weekMeasure blood pressure, blood lipid profiles, fasting glucose, and waist circumferences.

Secondary

MeasureTime frameDescription
Antioxidant activityUp to 1 weekAntioxidant ability measurements: lipid peroxidation markers (MDA), antioxidant enzymes activities (catalase, glutathione peroxidase, and superoxide dismutase).
Inflammatory statusUp to 1 weekMeasure inflammatory markers: C-reactive protein, Interleukin-6, and tumor necrosis factor-alpha.

Countries

Taiwan

Contacts

Primary ContactPing-Ting Lin, Ph.D.
apt810@csmu.edu.tw+886-4-23470022
Backup ContactBore-Jen Lee, Ph.D.
borjen@vghtc.gov.tw+886-4-23592525

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026